Centessa Pharmaceuticals plc

“How does it feel that you have a billion-dollar neuroscience commercial business, and no one cares?” That’s the question an investor asked Alkermes’ chief operating officer Blair Jackson at the recen

Biopharmaceutical companies celebrated recent positive data readouts with a slew of significant follow-on public offerings (FOPOs), including Nuvalent, Inc. , which grossed $500m on 16 September from

New PureTech Health plc CEO Bharatt Chowrira has been reflecting on a successful first six months of the year, with both the firm's wholly owned pipeline and those of its subsidiaries progressing we

A lot of biopharmaceutical companies have changed their strategies during the past year or two with investors less receptive to stock offerings in 2022 and 2023 than they were in the two prior years,